Work

An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression

Year: 2015

Type: article

Abstract: Meeting abstracts The prevalence of head and neck cancers in the USA is estimated to be about 370,000 and between 25% to 38% of these are human papilloma virus (HPV)-associated head and neck squamous cell carcinomas (HNSCC). We have developed a viral gene delivery platform to immunize against HPV

Source: Journal for ImmunoTherapy of Cancer

DOI: 10.1186/2051-1426-3-s2-p449

Authors: Adrian E Rice, Yvette Latchman, Joseph P Balint, John H Lee, Elizabeth S Gabitzsch, Frank R Jones

Institutions: Etubics (United States), University of South Dakota

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,490